CAMBRIDGE, Mass. – Amylyx Pharmaceuticals, Inc. today announced the closing of an oversubscribed $135 million Series C financing, led by Viking Global Investors, to support the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative...
finance News
New York, NY – Anavex Life Sciences was hit with a stock selloff on Tuesday after it posted topline results from a Phase II/III study for its candidate ANAVEX2-73 in pediatric patients with Rett syndrome. The study’s co-primary endpoint of the Clinical Global Impression-Improvement scale (CGI-I) was not reached, according...
Its emerging rare disease unit is driving sales growth for ANI Pharmaceuticals Inc. Looking ahead the company wants to build and expand rare disease drug sales. “The first imperative is scaling up our rare disease business,” said Nikhil Lalwani, chief executive of ANI, in a morning earnings conference call with...
ATLANTA — Purple Pansies, a pancreatic cancer nonprofit organization, recently held its 12th annual Pillars of Hope Gala, presented by Kroger, raising more than $1 million in one evening to help fund pancreatic cancer research at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. The gala...
VIENNA, Austria – Since 2017, PharmaEssentia had repeatedly attempted to terminate the agreement with AOP Orphan concerning BESREMi® (Ropeginterferon alfa-2b). After two and a half years of arbitral proceedings, in October 2020, the ICC Arbitral Tribunal issued its award in the matter. The arbitral award states that PharmaEssentia’s multiple attempts...
Aqilion has strengthened its pipeline with an innovative development program in the field of chronic inflammation. With this acquisition, Aqilion is taking over all rights to the program, now under the name Regulus, from LEO Pharma. The project is ready for clinical trials and Aqilion plans to begin clinical development in...
NEW YORK and BASEL, Switzerland – Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to its manufacturing, preclinical and clinical teams, a major milestone in the company’s strategy to build a beginning-to-end internal-external supply model led by its pioneering cell and...
LYON, France and CAMBRIDGE, Mass. — Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase price of $800 million upfront and a potential...
Drugmaker AstraZeneca today pushed deeper into the lucrative but high-risk rare diseases market, signing a cash deal worth up to $3.6 billion for rights to a promising treatment for an incurable liver condition. The FTSE 100’s most valuable company — which stunned investors last year with the $39 billion buy-up of rare...
The UK Competition and Markets Authority has cleared AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, Inc. (Alexion). As a result, the acquisition is expected to close on 21 July 2021. Following closing, the new AstraZeneca shares issued to Alexion shareholders will be admitted to listing on the premium listing segment of...